(Q41574578)

English

A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients

scientific article published on 6 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients (English)

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

author name string

Yi Liu

1

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Bing Liu

2

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Xiao-Yan Li

3

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Jian-Jie Li

4

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Hai-Feng Qin

5

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Chuan-Hao Tang

6

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Wan-Feng Guo

7

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Hai-Xu Hu

8

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Sha Li

9

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Cui-Jing Chen

10

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Bing Liu

11

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Hong-Jun Gao

12

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Xiao-Qing Liu

13

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

6 December 2011

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Journal of Experimental & Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

30

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

111

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

copyright license

Creative Commons Attribution 2.0 Generic

1 December 2011

1 reference

April 2022 Public Data File from Crossref

Creative Commons Attribution 2.0 Generic

0 references

copyright status

1 reference

April 2022 Public Data File from Crossref

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Circulating tumour cells in cancer patients: challenges and perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Circulating tumour cells in clinical practice: Methods of detection and possible characterization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

6 June 2018

RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

19 August 2018

Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

19 August 2018

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

19 August 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

19 August 2018

Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

19 August 2018

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-30-111

21 January 2018

Epidermal Growth Factor Receptor Double Activating Mutations Involving Both Exons 19 and 21 Exist in Chinese Non-small Cell Lung Cancer Patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3287118

2 December 2018

High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22142557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22142557

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1756-9966-30-111

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

4 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41574578&oldid=2204633320"